XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]        
Revenue $ 48,926 $ 43,660 $ 86,573 $ 82,280
Operating expenses        
Cost of revenue 17,910 13,221 36,591 26,413
Research and development 32,237 37,037 64,838 74,876
Sales and marketing 23,872 24,281 46,180 50,374
General and administrative 22,302 21,200 43,133 45,344
Amortization of intangible assets 423 423 842 842
Total operating expenses 96,744 96,162 191,584 197,849
Loss from operations (47,818) (52,502) (105,011) (115,569)
Interest and other income, net 3,612 418 6,636 689
Interest expense (3,605)   (7,136)  
Net loss (47,811) (52,084) (105,511) (114,880)
Add: Net loss attributable to noncontrolling interest 1 38 2 98
Net loss attributable to Adaptive Biotechnologies Corporation $ (47,810) $ (52,046) $ (105,509) $ (114,782)
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic $ (0.33) $ (0.37) $ (0.73) $ (0.81)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic 144,397,693 142,363,589 143,956,867 142,032,261
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted $ (0.33) $ (0.37) $ (0.73) $ (0.81)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted 144,397,693 142,363,589 143,956,867 142,032,261